Argenx SE ADR (ARGX) reported Thursday it swung to Q3 net profit of $1.39 per diluted share from $1.25 loss per share a year earlier.
Total operating income for the quarter ended Sept. 30 was $588.9 million, up from $339.8 million a year earlier.
The Dutch immunology company said with an increase in cash, cash equivalents and current financial assets in the quarter and year-to-date, the previously issued cash guidance no longer applies.
The financial guidance on the combined selling, general and administrative expenses and research and development expenses remains unchanged at approximately $2 billion.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。